Core Insights - The company reported a revenue of 27.617 billion yuan for 2024, representing a year-on-year growth of 11.63% [1] - The net profit attributable to shareholders reached 3.368 billion yuan, marking an 18.05% increase compared to the previous year [1] - Basic earnings per share were reported at 2.63 yuan [1] Dividend and Capital Increase - The company plans to distribute a cash dividend of 3.2 yuan (including tax) for every 10 shares [1] - Additionally, the company will increase capital by issuing 3 additional shares for every 10 shares held [1]

Financial Performance - The company's operating revenue for 2024 reached ¥27.62 billion, an increase of 11.63% compared to ¥24.74 billion in 2023[20]. - Net profit attributable to shareholders was ¥3.37 billion, reflecting an 18.05% increase from ¥2.85 billion in the previous year[20]. - The net profit after deducting non-recurring gains was ¥3.12 billion, up 15.01% from ¥2.71 billion in 2023[20]. - The cash flow from operating activities amounted to ¥4.40 billion, a 5.02% increase from ¥4.19 billion in the previous year[20]. - Basic earnings per share rose to ¥2.63, representing a 17.41% increase from ¥2.24 in 2023[21]. - Total assets at the end of 2024 were ¥40.08 billion, a slight decrease of 0.17% from ¥40.15 billion in 2023[21]. - The net assets attributable to shareholders increased by 4.93% to ¥19.90 billion from ¥18.97 billion in the previous year[21]. - The company reported a total of ¥250 million in non-recurring gains for 2024, compared to ¥141.95 million in 2023[26]. - The company achieved a diluted earnings per share of ¥2.63, up 17.94% from ¥2.23 in 2023[21]. - The weighted average return on equity was 17.33%, an increase from 15.86% in the previous year[21]. Dividend Distribution - The company plans to distribute a cash dividend of 3.2 RMB per 10 shares (including tax) and will issue 3 additional shares for every 10 shares held from capital reserves[5]. - The total cash dividend for the first three quarters of 2024 amounts to 1,284,298,685 RMB (including tax), with an annual total of 1,695,274,264.20 RMB (including tax), representing 50.34% of the net profit attributable to shareholders[5]. - The company completed its profit distribution for the first three quarters of 2024 in November 2024[5]. - Cumulative cash dividends from 2022 to 2024 will represent 144.15% of the average net profit attributable to shareholders over the last three years[127]. - The company implemented a cash dividend of 13.20 yuan per 10 shares, totaling approximately 1.284 billion yuan, which accounts for 50.34% of the net profit for the year[127]. Market and Industry Insights - The Chinese pharmaceutical retail market is projected to reach a sales scale of 501.9 billion yuan in 2024, with a year-on-year growth of 0.8%[30]. - The hospital pharmaceutical market size for the first nine months of 2024 is estimated at 751 billion yuan, with a year-on-year decline of 3.3%[31]. - The e-commerce channel for pharmaceutical sales reached 64.5 billion yuan in 2024, with a growth rate of 4.6%, outpacing physical stores[30]. - The pharmaceutical sector contributed ¥23.70 billion, accounting for 85.82% of total revenue, with a year-on-year growth of 12.78%[71]. - The self-care (CHC) segment generated ¥12.48 billion, making up 45.20% of total revenue, with a growth rate of 14.13%[72]. Research and Development - R&D investment has increased from 581 million yuan in 2020 to 953 million yuan in 2024, representing a growth of 63.97%[39]. - The company invested 0.953 billion yuan in R&D, with 131 ongoing projects focused on oncology, orthopedics, dermatology, respiratory, and anti-infection treatments[48]. - The company has established a systematic R&D framework with multiple research institutes focusing on innovative drug development and traditional Chinese medicine[39]. - The company conducted 131 new product research projects, including 4 Class 1 chemical drugs and 7 Class 1 traditional Chinese medicines, aimed at meeting clinical needs[81]. - The total amount of R&D investment in 2024 was ¥952,976,326.13, a 7.20% increase from ¥888,951,186.66 in 2023, with R&D investment accounting for 3.45% of operating income[81]. Strategic Initiatives - The company aims to become a leader in the public pharmaceutical health industry, focusing on high-quality product innovation and smart manufacturing[32]. - The company is actively pursuing strategic acquisitions, including a 51% stake in Kunming Pharmaceutical Group, to enhance its presence in the chronic disease management sector[63]. - The company is implementing a quality management system (QMS) upgrade across over ten production units, aiming to improve overall quality management levels[56]. - The company is focusing on digital quality management capabilities to strengthen its long-term sustainable development mechanisms[54]. - The company is committed to continuous product innovation and clinical research to support its commercial promotion activities[110]. Corporate Governance and Investor Relations - The company’s financial report has been confirmed for accuracy and completeness by its board of directors and senior management[3]. - The company is focused on enhancing corporate governance and investor relations, ensuring high standards of information disclosure and communication with investors[130]. - The company maintains independence from its controlling shareholder in terms of operations, personnel, assets, and finance, ensuring a clear separation of interests[133]. - The board of directors and supervisory board operate independently, with clear responsibilities and adherence to legal requirements[130]. - The company has established a market value management system to enhance investment value and protect the rights of stakeholders[124]. Sustainability and Compliance - The company is actively pursuing green and sustainable development, ensuring all pollutant emissions comply with national and local standards[54]. - The company is committed to biodiversity protection and promoting sustainable development of traditional Chinese medicine materials[55]. - The company is enhancing its compliance management system to mitigate legal risks and improve operational governance[68]. - The company is committed to environmental sustainability, including the creation of green and low-carbon factories[104]. - The company is focused on maintaining compliance with relevant laws and regulations to ensure sustainable growth[124]. Future Outlook - The company anticipates continued pressure in the pharmaceutical industry in 2025, focusing on sustainable growth and mergers and acquisitions[103]. - The company expects a capital expenditure of approximately 1 billion CNY for fixed asset projects, with a total operating capital requirement of about 2.9 billion CNY for 2025[108]. - The company plans to enhance innovation investment and accelerate pipeline innovation, with a focus on traditional Chinese medicine and new drug development[103]. - The company is exploring potential mergers and acquisitions to enhance its market position and diversify its product offerings[141]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 12% to 15%[151].

华润三九医药股份有限公司 自 2024 年 1 月 1 日 至 2024 年 12 月 31 日止年度内部控制审计报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 内部控制审计报告 华润三九医药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了华润 三九医药股份有限公司 (以下简称"贵公司") 2024 年 12 月 31 日的财务报告内部控制的有效 性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指 ...

华润三九医药股份有限公司 自 2024 年 1 月 1 日 至 2024 年 12 月 31 日止年度财务报表 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2501575 号 华润三九医药股份有限公司全体股东： 一、审计意见 我们审计了后附的华润三九医药股份有限公司 (以下简称"华润三九") 的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母 公司现金流量表、合并及母公司股东权益变动表 ...

华润三九医药股份有限公司 独立董事 2024 年度述职情况报告 本人作为华润三九医药股份有限公司（以下简称"公司"）独立董事，严格按照《公司 法》《上市公司独立董事管理办法》《公司章程》《华润三九独立董事工作制度》等规定，忠 实、勤勉、尽责地履行独董职责，主动了解公司生产经营情况，出席了公司相关会议，充分 发挥自身的专业优势和独立作用，认真审议董事会的各项议案并发表独立意见，切实维护了 公司和广大股东尤其是中小股东的利益。 本人为 2024 年 5 月 15 日公司召开 2024 年第二次临时股东大会换届选举产生的新任独 立董事，现任公司独立董事、董事会薪酬与考核委员会委员、董事会审计委员会委员职务。 现将本人 2024 年的履职情况报告如下： 一、 基本情况 1.独立董事基本情况 王轶先生（2024 年 5 月 15 日-2024 年 12 月 31 日）：曾任阿里巴巴集团天猫优品事业 部总经理、天猫生鲜事业部总经理，TCL 多媒体 CFO 兼中国事业部总经理、TCL 电子执行董 事/高级副总裁，TCL 实业副总裁及中国营销本部总经理。现任深圳明微管理咨询有限公司 总经理，华润三九医药股份有限公司独立董事。 ...

华润三九医药股份有 限公司董事会 华润三九医药股份有限公司董事会 二〇二五年三月十二日 根据证监会《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要求，华润 三九医药股份有限公司（以下简称"公司"）董事会就公司独立董事贺震旦先生、李梦 涓女士、孙健先生、王轶先生、张强先生、姚兴田先生、许芳女士、刘俊勇先生的独立 性情况进行评估并出具如下专项意见： 经核查，独立董事贺震旦先生、李梦涓女士、孙健先生、王轶先生、张强先生、姚 兴田先生、许芳女士、刘俊勇先生的任职经历以及签署的相关自查文件，上述人员未在 公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司 以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，因此， 公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等法律法规及《公司章程》中对独立董事独立 性的相关要求。 关 于独 立董 事独立 性情 况的 专项意 见 ...

华润三九医药股份有限公司 独立董事 2024 年度述职情况报告 本人作为华润三九医药股份有限公司（以下简称"公司"）独立董事，严格按照《公司 法》《上市公司独立董事管理办法》《公司章程》《华润三九独立董事工作制度》等规定，忠 实、勤勉、尽责地履行独董职责，主动了解公司生产经营情况，出席了公司相关会议，充分 发挥自身的专业优势和独立作用，认真审议董事会的各项议案并发表独立意见，切实维护了 公司和广大股东尤其是中小股东的利益。 本人为2024年2月2日公司召开2024年第一次临时股东大会选举产生的新任独立董事， 现任公司独立董事、董事会审计委员会主任委员及委员职务。现将本人 2024 年的履职情况 报告如下： 一、 基本情况 1.独立董事基本情况 孙健先生（2024 年 2 月 2 日-2024 年 12 月 31 日）：2009 年 7 月至今任教于中央财经 大学会计学院，历任会计学实验室主任、会计信息系主任，现任中央财经大学会计学院副院 长、教授、博士生导师。财政部会计领军人才学术类（第四期），财政部全国会计信息化标 准化技术委员会咨询专家。2015 年起,先后担任熊猫金控股份有限公司、方正证券承销保荐 有限 ...

华润三九医药股份有限公司 华润三九医药股份有限公司 第一章 总则 第一条 为规范公司投资者关系管理工作，加强公司与投资者 之间的有效沟通，促进公司完善治理，提高公司的诚信度和投资价值， 根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所股票上市规则》《上市公司投资者关系管理工作指引》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》 等有关法律法规和规章等，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信 息披露、互动交流和诉求处理等工作，加强与投资者及潜在投资者之 间的沟通，增进投资者对公司的了解和认同，以提升公司治理水平和 企业整体价值，实现尊重投资者、回报投资者、保护投资者目的的相 关活动，是获取投资者认同和支持、完善公司的治理结构、促进公司 规范运作的重要渠道。 第三条 公司投资者关系管理工作应严格遵守有关法律、法规、 规章及深圳证券交易所（以下简称"深交所"）有关规定及本公司《公 司章程》的规定。 第四条 公司投资者关系管理的基本原则是： （一）合规性原则。公司投资者关系管理应当在依法履行信息披 露义务的基础上开展，符合法律、法规、规 ...